Document Type

Article

Publication Date

2-15-2022

Comments

This article is the author’s final published version in Cancer Research, Volume 82, Issue 4, February 2022, Pages 523 - 533

The published version is available at https://doi.org/10.1158/0008-5472.CAN-21-1756. Copyright © 2022 American Association for Cancer Research Inc.. All rights reserved.

Abstract

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a pleiotropic protein kinase that plays critical roles in cellular processes fundamental to cancer. DNA-PKcs expression and activity are frequently deregulated in multiple hematologic and solid tumors and have been tightly linked to poor outcome. Given the potentially influential role of DNA-PKcs in cancer development and progression, therapeutic targeting of this kinase is being tested in preclinical and clinical settings. This review summarizes the latest advances in the field, providing a comprehensive discussion of DNA-PKcs functions in cancer and an update on the clinical assessment of DNA-PK inhibitors in cancer therapy.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

34893509

Language

English

Share

COinS